Retatrutide 6mg
First-in-class triple agonist peptide targeting GLP-1, GIP, and glucagon receptors for profound metabolic and weight regulation research.
Mechanism
Retatrutide acts as a unimolecular triple agonist targeting the GLP-1, GIP, and glucagon receptors to synergistically enhance satiety, optimize glucose regulation, and augment energy expenditure.
Dosing
Documented laboratory investigations initiate the peptide at a starting dose of 2 mg administered subcutaneously once per week.
Reconstitution
Reconstituting a 6 mg vial with 1.2 mL of bacteriostatic water yields an operational working concentration of 5 mg/mL.
Storage
Store the unmixed lyophilized powder frozen at -20 °C, and once reconstituted, maintain the solution refrigerated at 2–8 °C for up to 4 weeks shielded from light.
Mix & measure Retatrutide 6mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure Retatrutide 6mg
Vial strength → BAC water → target dose
Common vial sizes
Label claim
Total doses in vial: 3.0
U-100 syringe: 100 units = 1 mL
Need supplies for this protocol?
Research-grade peptides, fast shipping, competitive pricing
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Track my protocol
Log each dose, build a streak, and watch your progress through this protocol's schedule.
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Weeks 1–4 | 2 mg once weekly | 40 units (0.40 mL) |
| Weeks 5–8 | 4 mg once weekly | 80 units (0.80 mL) |
| Weeks 9–12 | 8 mg once weekly | 160 units (1.60 mL) — requires 2 vials |
| Weeks 13+ | 12 mg once weekly | 240 units (2.40 mL) — requires 2 vials |
Reconstitution Steps
- 1
Draw exactly 1.2 mL of bacteriostatic water into a sterile syringe.
- 2
Introduce the needle into the 6 mg vial and discharge the diluent slowly down the glass wall to minimize agitation.
- 3
Gently rotate and swirl the vial until the lyophilized cake is entirely dissolved without vigorously shaking.
- 4
Record the date of reconstitution and place the solution in refrigeration at 2–8 °C protected from light exposure.
Supplies Needed
Peptide Vial
Lyophilized retatrutide 6 mg powder intended for reconstituting research solutions.
Insulin Syringes (U-100)
Precision U-100 (1 mL) syringes used for accurate dosing volume measurement and subcutaneous delivery.
Bacteriostatic Water
Sterile diluent containing 0.9% benzyl alcohol utilized to reconstitute the peptide cake.
Alcohol Swabs
Disinfectant wipes applied to sanitize vial rubber stoppers and clean targeted administration sites.
Why researchers study it
Investigation of substantial body-weight reduction via triple-receptor agonism
Appetite suppression and modulation of food intake through GLP-1 and GIP signaling
Glycemic regulation and metabolic parameter management in diabetes models
Reduction of hepatic steatosis through targeted glucagon receptor activation
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
Retatrutide is an investigational multi-incretin mimetic engineered to simultaneously engage three key metabolic pathways: the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. By coordinating signaling across these distinct endocrine axes, the compound drives synergistic alterations in appetite suppression, insulin sensitivity, and resting energy expenditure. Preclinical models and clinical investigations highlight retatrutide as a significant progression beyond single- and dual-incretin receptor agonists. Its distinct inclusion of glucagon receptor agonism promotes enhanced hepatic lipid metabolism and thermogenesis, addressing core drivers of metabolic dysfunction without sacrificing glycemic balance. Due to an optimized molecular structure that provides an elimination half-life of approximately six days, retatrutide is routinely studied via once-weekly subcutaneous administrations. Research protocols emphasize deliberate, multi-week dose titration schedules to assess sustained metabolic shifts while optimizing subject tolerability throughout extended investigational courses.
References
- 1.Jastreboff et al., New England Journal of Medicine, 2023 — Triple-Hormone-Receptor Agonist Retatrutide for Obesity
- 2.Rosenstock et al., The Lancet, 2023 — Retatrutide in type 2 diabetes: Phase 2 trial
- 3.Frias et al., JAMA Network, 2023 — Retatrutide Phase 2 Obesity Trial: detailed efficacy and safety data
- 4.Metabolites (PMC), 2025 — Retatrutide—A Game Changer in Obesity Pharmacotherapy
- 5.Baylor University Medical Center Proceedings, 2025 — Efficacy and safety of retatrutide for obesity: meta-analysis of RCTs
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View all5-Amino-1MQ 10mg
Synthetic small-molecule NNMT inhibitor explored in preclinical models for cellular energy balance, NAD+ preservation, and adipocyte metabolism.
View ProtocolCJC-1295 DAC 5mg
Long-acting synthetic GHRH analog paired with Drug Affinity Complex to sustain growth hormone release in laboratory models.
View ProtocolTesamorelin 10mg
Tesamorelin is a stabilized synthetic GHRH analog researched for visceral adipose tissue reduction and endogenous growth hormone release.
View Protocol